Insulin Reduces Plasma Arginase Activity in Type 2 Diabetic Patients

Abstract

OBJECTIVE—We sought to determine whether dysregulation of arginine metabolism is related to insulin resistance and underlies impaired nitric oxide (NO) generation in type 2 diabetic patients. RESEARCH DESIGN AND METHODS—We measured plasma arginase activity, arginine metabolites, and skeletal muscle NO synthase (NOS) activity in 12 type 2 diabetic and 10 age-/BMI-matched nondiabetic subjects before and following a 4-h euglycemic-hyperinsulinemic clamp with muscle biopsies. Arginine metabolites were determined by tandem mass spectroscopy. Arginase activity was determined by conversion of [14C] guanidoinoarginine to [14C] urea. RESULTS—Glucose disposal (Rd) was reduced by 50% in diabetic versus control subjects. NOS activity was fourfold reduced in the diabetic group (107 ± 45 vs. 459 ± 100 pmol · min−1 · mg protein−1; P < 0.05) and failed to increase with insulin. Plasma arginase activity was increased by 50% in the diabetic versus control group (0.48 ± 0.11 vs. 0.32 ± 0.12 μmol · ml−1 · h−1; P < 0.05) and markedly declined in diabetic subjects with 4-h insulin infusion (to 0.13 ± 0.04 μmol · ml−1 · h−1 vs. basal; P < 0.05). In both groups collectively, plasma arginase activity correlated positively with fasting plasma glucose (R = 0.46, P < 0.05) and A1C levels (R = 0.51, P < 0.02) but not with Rd. CONCLUSIONS—Plasma arginase activity is increased in type 2 diabetic subjects with impaired NOS activity, correlates with the degree of hyperglycemia, and is reduced by physiologic hyperinsulinemia. Elevated arginase activity may contribute to impaired NO generation in type 2 diabetes, and insulin may ameliorate this defect via reducing arginase activity.